Dermatology

There are 3 classes of nonsteroidal topical therapies for atopic dermatitis that target the specific underlying pathophysiology of the skin disease. Shahriari provides a primer.

Rebecca Hartman, MD, MHP, assistant professor of dermatology at Brigham and Women's Hospital and Harvard Medical School, reviews new point-of-care detection technology.

Topical corticosteroids, once revolutionary for treatment of atopic dermatitis, are used just sparingly today; dermatologist Mona Shahriari, MD, lists the reasons.

Dermatologist Rebecca Hartman, MD, MPH, said that reliable point-of-care screening results can help reduce unnecessary specialist referral for benign lesions.

Not all atopic dermatitis requires treatment by a specialist, says this dermatologist, and she collaborates regularly with her primary care colleagues.

The DermaSensor skin cancer screening device was pitted against clinical impressions of lesions suspected with high confidence to be melanoma. Results, here.

Dermatologists at high volume dermatology centers referred suspicious lesions to pathology for biopsy and diagnosis. The results were compared with DermaSensor read-outs.

A rapid increase in the rate of melanoma diagnoses could be the result of multiple factors, explains the Harvard assistant professor of dermatology.

A bothersome skin lesion is typically first seen and assessed in primary care. An AI-based point-of-care device may help enhance triage, says Rebecca Hartman, MD, MPH.

Shahriari, assistant clinical professor of dermatology at Yale University School of Medicine, says greater understanding of the condition has expanded the population for the diagnosis.

Dermatology thought leader Mona Shihriari, MD, offers a brief overview of the inflammatory skin disease for primary care clinicians.

Updated mRNA COVID-19 vaccines, the first orally disintegrating tablet approved for pregnancy prevention, and 5 more.

Roflumilast cream 0.15% was associated with consistent and meaningful improvements in AD clearance and itch reduction, according to new data.

Delgocitinib specifically inhibits activation of JAK-STAT signaling in chronic hand eczema and would be an option for people unable to use topical corticosteroids.

Your daily dose of the clinical news you may have missed.

The AI-based point-of-care device outperformed clinician standard of care for sensitivity (90% vs 40%) and had a negative predictive value of 98.9%

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Among those treated with lebrikizumab, more than one-third saw clear/almost clear skin at week 16; three-quarters of them maintained results at week 52 with monthly dosing.

The term "flare" is used consistently in discussions of AD, but is everyone talking about the same thing? New research closes in on a patient-centered definition.

In a study of persons with moderate-to-severe atopic dermatitis, lebrikizumab monotherapy for 16 weeks resulted in improved quality of life and mental health.

In a study of patients with atopic dermatitis, tralokinumab was effective and safe in elderly patients and those with severe comorbidities.

In a study of patients with CHE, 75.5% of participants totally or almost agreed that topical corticosteroids cause damage to skin.

Your daily dose of the clinical news you may have missed.

The steroid-free cream was developed for long-term use and has been proven safe in an open-label extension study following successful phase 3 trials.

The FDA PDUFA date for taparinof cream 1% will be during the 4th quarter, Dermavant said, with approval based on ADORING phase 3 clinical trial data.

Your daily dose of the clinical news you may have missed.

Study participants self-identified as Black, White, or Asian and significant proportions reached improvement of ≥75% in EASI in both in ADORING 1 and ADORING-2.

AAAAI 2024. Reduction of AD signs and symptoms was significant among approximately half of study participants at 4 weeks and continuously rose through week 260, investigators report.

AAAAI 2024. The effects, seen 18 to 20 weeks after discontinuation of tezepelumab, suggest a persistent effect of thymic stromal lymphopoietin (TSLP) blockade in CSU.